Study identifier:D169AC00007
ClinicalTrials.gov identifier:NCT05306210
EudraCT identifier:N/A
CTIS identifier:N/A
Forxiga tablets 5mg, 10mgGeneral Drug Use-Results Study n in chronic kidney disease (CKD) patients
Chronic Kidney Disease
N/A
No
-
All
1029
Observational
n/a - n/a
Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Dec 2024 by AstraZeneca
AstraZeneca
-
To capture safety when Forxige is administrated to CKD patients in the real world setting
The purpose of the study is to review the following points during use of Forxiga Tablets (hereinafter referred to as Forxiga) in the real world setting after launch for treatment of CKD. (1) ADRs which are unexpected from the precautions for use in our JPI (2) Understanding of incidence of ADRs during use of Forxiga in the real world setting (3) Factors (ie demography, treatment) possibly having an impact on the safety.
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.